These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 34779530)

  • 21. Reactive Myelopoiesis Triggered by Lymphodepleting Chemotherapy Limits the Efficacy of Adoptive T Cell Therapy.
    Innamarato P; Kodumudi K; Asby S; Schachner B; Hall M; Mackay A; Wiener D; Beatty M; Nagle L; Creelan BC; Sarnaik AA; Pilon-Thomas S
    Mol Ther; 2020 Oct; 28(10):2252-2270. PubMed ID: 32615068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adoptive T cell therapy: points to consider.
    Yee C
    Curr Opin Immunol; 2018 Apr; 51():197-203. PubMed ID: 29730057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy.
    Elia AR; Grioni M; Basso V; Curnis F; Freschi M; Corti A; Mondino A; Bellone M
    Clin Cancer Res; 2018 May; 24(9):2171-2181. PubMed ID: 29490991
    [No Abstract]   [Full Text] [Related]  

  • 24. The use of endogenous T cells for adoptive transfer.
    Yee C
    Immunol Rev; 2014 Jan; 257(1):250-63. PubMed ID: 24329802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adoptive Cell Therapy--Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors.
    Feldman SA; Assadipour Y; Kriley I; Goff SL; Rosenberg SA
    Semin Oncol; 2015 Aug; 42(4):626-39. PubMed ID: 26320066
    [No Abstract]   [Full Text] [Related]  

  • 26. Aging: T cell metabolism within tumors.
    Zhang Y; Ertl HC
    Aging (Albany NY); 2016 Jun; 8(6):1163-4. PubMed ID: 27282177
    [No Abstract]   [Full Text] [Related]  

  • 27. Immune-mediated anti-tumor effects of metformin; targeting metabolic reprogramming of T cells as a new possible mechanism for anti-cancer effects of metformin.
    Bahrambeigi S; Shafiei-Irannejad V
    Biochem Pharmacol; 2020 Apr; 174():113787. PubMed ID: 31884044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of Mitochondria in Cancer Immune Evasion and Potential Therapeutic Approaches.
    Klein K; He K; Younes AI; Barsoumian HB; Chen D; Ozgen T; Mosaffa S; Patel RR; Gu M; Novaes J; Narayanan A; Cortez MA; Welsh JW
    Front Immunol; 2020; 11():573326. PubMed ID: 33178201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. To Remember or to Forget: The Role of Good and Bad Memories in Adoptive T Cell Therapy for Tumors.
    Mondino A; Manzo T
    Front Immunol; 2020; 11():1915. PubMed ID: 32973794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.
    Schlenker R; Olguín-Contreras LF; Leisegang M; Schnappinger J; Disovic A; Rühland S; Nelson PJ; Leonhardt H; Harz H; Wilde S; Schendel DJ; Uckert W; Willimsky G; Noessner E
    Cancer Res; 2017 Jul; 77(13):3577-3590. PubMed ID: 28533272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Editorial: Tissue Resident Memory T Cells.
    Mami-Chouaib F; Tartour E
    Front Immunol; 2019; 10():1018. PubMed ID: 31191515
    [No Abstract]   [Full Text] [Related]  

  • 32. Cellular immunotherapy of cancer: an overview and future directions.
    Tao Z; Li S; Ichim TE; Yang J; Riordan N; Yenugonda V; Babic I; Kesari S
    Immunotherapy; 2017 Jun; 9(7):589-606. PubMed ID: 28595516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CAR T Cell Therapy for Solid Tumors.
    Newick K; O'Brien S; Moon E; Albelda SM
    Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression.
    Wang Y; Sun SN; Liu Q; Yu YY; Guo J; Wang K; Xing BC; Zheng QF; Campa MJ; Patz EF; Li SY; He YW
    Cancer Discov; 2016 Sep; 6(9):1022-35. PubMed ID: 27297552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Next generation engineered T cells for cell therapy: from lymphoma to solid tumors].
    Catros V
    Med Sci (Paris); 2019 Apr; 35(4):316-326. PubMed ID: 31038109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy Approaches Beyond PD-1 Inhibition: the Future of Cellular Therapy for Head and Neck Squamous Cell Carcinoma.
    Qureshi HA; Lee SM
    Curr Treat Options Oncol; 2019 Mar; 20(4):31. PubMed ID: 30874960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation.
    Zhou S; Meng F; Du S; Qian H; Ding N; Sha H; Zhu M; Yu X; Wang L; Liu B; Wei J
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986122
    [TBL] [Abstract][Full Text] [Related]  

  • 39. One size does not fit all: personalized immune therapies poised to take center stage.
    Azvolinsky A
    J Natl Cancer Inst; 2013 May; 105(9):583-4. PubMed ID: 23591459
    [No Abstract]   [Full Text] [Related]  

  • 40. T lymphocyte therapy of cancer.
    Michálek J; Büchler T; Hájek R
    Physiol Res; 2004; 53(5):463-9. PubMed ID: 15479123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.